Evoke Pharma has appointed Marilyn Carlson as Chief Medical Officer and Wayne Alves as Senior Director of Clinical Operations. The company is planning to begin a Phase 3 clinical trial of EVK-001 intranasal metoclopramide for gastroparesis, which is expected to commence in the first half of 2014.
Evoke President and CEO Dave Gonyer said, “Dr. Carlson and Dr. Alves represent key corporate appointments as Evoke advances toward the initiation of its Phase 3 trial and adds staff to help ensure a timely initiation and execution. With the funding from our recent initial public offering in place, we are well positioned to advance the development of EVK-001 toward FDA approval and commercialization.
SynteractHCR has been selected as the primary CRO for the Phase 3 trial.
Read the Evoke press release.
